The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource-Reference-Cited by-同舟云学术

The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource

Published:2022-02-07 Issue:4 Volume:31 Page:715-727
ISSN:1055-9965
Container-title:Cancer Epidemiology, Biomarkers & Prevention
language:en
Short-container-title:

Author:

Ouellet Véronique¹^ORCID,Erickson Andrew²³⁴,Wiley Kathy⁴,Morrissey Colm⁵,Berge Viktor⁶,Moreno Carlos S.⁷⁸^ORCID,Tasken Kristin Austlid⁹¹⁰^ORCID,Trudel Dominique¹¹¹^ORCID,True Lawrence D.¹²,Lewis Michael S.¹³,Svindland Aud¹⁰¹⁴,Ertunc Onur⁴¹⁵^ORCID,Vidal Igor Damasceno⁴,Osunkoya Adeboye O.⁷⁸^ORCID,Jones Tracy⁴,Bova G. Steven¹⁶^ORCID,Lamminen Tarja¹⁷,Achtman Ariel H.¹⁸,Buzza Mark¹⁸,Kouspou Michelle M.¹⁸,Bigler Steven A.¹⁹,Zhou Xinchun²⁰,Freedland Stephen J.²¹²²,Mes-Masson Anne-Marie¹²³^ORCID,Garraway Isla P.²⁴²⁵,Trock Bruce J.²⁶^ORCID,Taimen Pekka²⁷²⁸^ORCID,Saad Fred¹²⁹,Mirtti Tuomas³⁰³¹^ORCID,Knudsen Beatrice S.³²^ORCID,De Marzo Angelo M.⁴²⁶³³^ORCID,

Affiliation:

1. 1Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.

2. 2Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.

3. 3Department of Pathology, Helsinki and Uusimaa Hospital District and Medicum, University of Helsinki, Helsinki, Finland.

4. 4Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

5. 5Department of Urology, University of Washington, Seattle, Washington.

6. 6Department of Urology, Oslo University Hospital, Oslo, Norway.

7. 7Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.

8. 8Winship Cancer Institute of Emory University, Atlanta, Georgia.

9. 9Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.

10. 10Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

11. 11Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Canada.

12. 12Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.

13. 13West Los Angeles Veterans Affairs Medical Center and Departments of Pathology and Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

14. 14Department of Pathology, Oslo University Hospital, Oslo, Norway.

15. 15Suleyman Demirel University, Department of Pathology, Training and Research Hospital East Campus, Isparta, Turkey.

16. 16Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, Finland.

17. 17Institute of Biomedicine, University of Turku, Turku, Finland.

18. 18Movember, Melbourne, Australia.

19. 19Department of Pathology, Mississippi Baptist Medical Center, Jackson, Mississippi.

20. 20Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.

21. 21Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California.

22. 22Section of Urology, Durham VA Medical Center, Durham, North Carolina.

23. 23Department of Medicine, Université de Montréal, Montreal, Canada.

24. 24Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, California.

25. 25Division of Urology, Greater Los Angeles VA Healthcare System, Los Angeles, California.

26. 26Department of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

27. 27Institute of Biomedicine, University of Turku, Turku, Finland.

28. 28Department of Pathology, Turku University Hospital, Turku, Finland.

29. 29Department of Surgery, Université de Montréal, Montreal, Canada.

30. 30HUS Diagnostic Center, Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland.

31. 31Medicum and Research Program In Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

32. 32Digital and Computational Pathology, University of Utah, Salt Lake City, Utah.

33. 33Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Abstract

Abstract Background: The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations. Methods: Three separate TMA sets were built that differ by purpose and disease state. Results: The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases. Conclusions: The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation. Impact: This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

Funder

U.S. NIH NCI SPORE in Prostate Cancer

U.S. Department of Defense Prostate Cancer Research Program

U.S. NIH NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology,Epidemiology

Link

https://aacrjournals.org/cebp/article-pdf/31/4/715/3191452/715.pdf

Reference35 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Recent global patterns in prostate cancer incidence and mortality rates;Culp;Eur Urol,2020

3. Overdiagnosis and overtreatment of prostate cancer;Loeb;Eur Urol,2014

4. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schröder;Lancet,2014

5. Active Surveillance for Localized Prostate Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer;The Journal of Pathology;2024-04-05